
Thierry Voisin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4464307/publications.pdf Version: 2024-02-01



THIEDDY VOISIN

#	Article	IF	CITATIONS
1	PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. Journal of Clinical Investigation, 2001, 108, 1483-1494.	8.2	181
2	Orexins and their receptors: structural aspects and role in peripheral tissues. Cellular and Molecular Life Sciences, 2003, 60, 72-87.	5.4	107
3	Identification and Distribution of mRNA Encoding the Y1, Y2, Y4, and Y5 Receptors for Peptides of the PP-fold Family in the Rat Intestine and Colon. Biochemical and Biophysical Research Communications, 1998, 247, 52-56.	2.1	94
4	Orexins Acting at Native OX1 Receptor in Colon Cancer and Neuroblastoma Cells or at Recombinant OX1 Receptor Suppress Cell Growth by Inducing Apoptosis. Journal of Biological Chemistry, 2004, 279, 45875-45886.	3.4	93
5	Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: an Openable Gate to Apoptosis. Cancer Research, 2011, 71, 3341-3351.	0.9	79
6	Regional Expression of Epithelial Dipeptidyl Peptidase IV in the Human Intestines. Biochemical and Biophysical Research Communications, 1994, 203, 1224-1229.	2.1	69
7	Neurotensin Receptor and Its mRNA Are Expressed in Many Human Colon Cancer Cell Lines But Not in Normal Colonic Epithelium: Binding Studies and RT-PCR Experiments. Biochemical and Biophysical Research Communications, 1994, 203, 465-471.	2.1	68
8	Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats. Pflugers Archiv European Journal of Physiology, 1995, 431, 66-75.	2.8	57
9	Orexin-Induced Apoptosis: The Key Role of the Seven-Transmembrane Domain Orexin Type 2 Receptor. Endocrinology, 2006, 147, 4977-4984.	2.8	51
10	Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosa Journal of Clinical Investigation, 1993, 91, 2049-2057.	8.2	51
11	A hallmark of immunoreceptor, the tyrosineâ€based inhibitory motif ITIM, is present in the G proteinâ€coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB Journal, 2008, 22, 1993-2002.	0.5	50
12	Discovery of a functional immunoreceptor tyrosine―based switch motif in a 7â€ŧransmembraneâ€spanning receptor: role in the orexin receptor OX1Râ€driven apoptosis. FASEB Journal, 2009, 23, 4069-4080.	0.5	48
13	The Peptide YY-Preferring Receptor Mediating Inhibition of Small Intestinal Secretion Is a Peripheral Y2 Receptor: Pharmacological Evidence and Molecular Cloning. Molecular Pharmacology, 2001, 60, 124-134.	2.3	47
14	Several Receptors Mediate the Antisecretory Effect of Peptide YY, Neuropeptide Y, and Pancreatic Polypeptide on VIP-Induced Fluid Secretion in the Rat Jejunum In Vivo. Peptides, 1997, 18, 551-557.	2.4	41
15	Effects of lactoferrin on intestinal epithelial cell growth and differentiation: an in vivo and in vitro study. BioMetals, 2014, 27, 857-874.	4.1	41
16	Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Frontiers in Endocrinology, 2019, 10, 709.	3.5	41
17	Orexins/hypocretins and orexin receptors in apoptosis: a miniâ€review. Acta Physiologica, 2010, 198, 393-402.	3.8	36
18	The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. European Journal of Cancer, 2014, 50, 2126-2133.	2.8	31

THIERRY VOISIN

#	Article	IF	CITATIONS
19	Structureâ^'Activity Studies Including a Î [.] (CH2-NH) Scan of Peptide YY (PYY) Active Site, PYY(22â^'36), for Interaction with Rat Intestinal PYY Receptors:  Development of Analogues with Potent in Vivo Activity in the Intestine. Journal of Medicinal Chemistry, 2000, 43, 3420-3427.	6.4	30
20	The orexin receptor OX ₁ R in colon cancer: a promising therapeutic target and a new paradigm in G proteinâ€coupled receptor signalling through ITIMs. British Journal of Pharmacology, 2012, 165, 1678-1687.	5.4	30
21	Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver. FEBS Journal, 1990, 187, 605-609.	0.2	29
22	Orexins Control Intestinal Glucose Transport by Distinct Neuronal, Endocrine, and Direct Epithelial Pathways. Diabetes, 2007, 56, 2494-2500.	0.6	28
23	Identification and functional studies of a specific peptide YY- preferring receptor in dog adipocytes. Endocrinology, 1992, 131, 1970-1976.	2.8	26
24	Gαi RNA Antisense Expression Demonstrates the Exclusive Coupling of Peptide YY Receptors to Gi2 Proteins in Renal Proximal Tubule Cells. Journal of Biological Chemistry, 1996, 271, 574-580.	3.4	24
25	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Frontiers in Endocrinology, 2018, 9, 573.	3.5	24
26	Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS ONE, 2017, 12, e0169908.	2.5	23
27	4 Receptors for gut regulatory peptides. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 77-110.	1.0	19
28	Crucial role of the orexinâ€B Câ€ŧerminus in the induction of OX ₁ receptorâ€mediated apoptosis: analysis by alanine scanning, molecular modelling and siteâ€directed mutagenesis. British Journal of Pharmacology, 2015, 172, 5211-5223.	5.4	19
29	<i>In vitro</i> , <i>in vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget, 2018, 9, 6952-6967.	1.8	19
30	Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium. Life Sciences, 1989, 45, 829-833.	4.3	17
31	Receptors for Peptides of the VIP/PACAP and PYY/NPY/PP Families. , 1999, , 125-157.		14
32	Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World Journal of Gastroenterology, 2021, 27, 7582-7596.	3.3	14
33	Structure-activity studies of peptide YY(22–36): , a potent antisecretory peptide in rat jejunum. Peptides, 1993, 14, 1011-1016.	2.4	13
34	Comparison of the Antisecretory Effect of Endogenous Forms of Peptide YY on Fed and Fasted Rat Jejunum. Peptides, 1997, 18, 1249-1255.	2.4	13
35	Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 631-638.	1.1	11
36	The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Frontiers in Oncology, 0, 12, .	2.8	7

THIERRY VOISIN

#	Article	IF	CITATIONS
37	VIP receptors from porcine liver: High yield solubilization in a GTP-insensitive form. Life Sciences, 1991, 48, 135-141.	4.3	6
38	Pharmacological profile of the rat intestinal crypt peptide YY receptor vs. the recombinant rat Y5 receptor. European Journal of Pharmacology, 1998, 362, 245-249.	3.5	6
39	Partial Knockdown of Cαi2Protein Is Sufficient to Abolish the Coupling of PYY Receptors to Biological Response in Renal Proximal Tubule Cells. Biochemical and Biophysical Research Communications, 1996, 225, 16-21.	2.1	5
40	Gut Peptide Receptors and Signal Transduction in Intestinal Epithelium: State of the Art. Frontiers of Gastrointestinal Research, 0, , 21-33.	0.1	3
41	Intestinal epithelial cells express leptin receptors that modulate the oligopeptide transporter Pept-1. Gastroenterology, 2000, 118, A604.	1.3	2
42	Common VIP / PACAP receptor in human small intestinal epithelium. Regulatory Peptides, 1992, 40, 242.	1.9	1
43	Tu1498 The Hypothalamic Neuropeptide, Orexin, Prevents Chronic Pancreatitis in Cerulein Mice Model. Gastroenterology, 2016, 150, S917.	1.3	1
44	Interplay between VIP and PYY/NPY receptors during enterocytic differentiation along the crypt-villus axis in rat small intestine. Regulatory Peptides, 1989, 26, 183.	1.9	0
45	Tu1834 Orexins Exert a PRO-Apoptotic Effect on Digestive Human Neuroendocrine Tumors (NET) in an Ex-Vivo Culture Model of Tissue Slices. Gastroenterology, 2012, 142, S-857.	1.3	0
46	Orexins (Hypocretins). , 2013, , 541-547.		0
47	Abstract 1215: Orexin and their 7-membrane spanning receptors OX1R: a new colon cancer therapeutic target. , 2012, , .		0
48	Abstract 4214: Antitumoral effects of orexins and their receptors OX1R in pancreatic ductal adenocarcinomas (PDAC). , 2014, , .		0
49	Abstract 4581: Combination treatment of orexin-A and NAB-paclitaxel in pancreas cancer:in vitroandin vivostudies. , 2016, , .		0